# Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis

Study · id `cardio:ct-nct02253654` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02253654](<https://clinicaltrials.gov/study/NCT02253654>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02253654

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 216 participants.

## Technical summary

Registry record NCT02253654. Randomized; triple masking; primary purpose treatment. Start 2015-04-01 (actual); primary completion 2016-04-27 (actual). Results posted on 2017-05-12.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 216 participants (enrolled count; ClinicalTrials.gov record NCT02253654, source copy `cardio:ctgov-nct02253654-2017-05-19`, retrieved 2026-10-26)
- Started: 2015-04-01 (actual) (ClinicalTrials.gov record NCT02253654, source copy `cardio:ctgov-nct02253654-2017-05-19`, retrieved 2026-10-26)
- Primary completion: 2016-04-27 (actual) (ClinicalTrials.gov record NCT02253654, source copy `cardio:ctgov-nct02253654-2017-05-19`, retrieved 2026-10-26)
- Completion: 2016-05-25 (actual) (ClinicalTrials.gov record NCT02253654, source copy `cardio:ctgov-nct02253654-2017-05-19`, retrieved 2026-10-26)
- Results first posted: 2017-05-12 (ClinicalTrials.gov record NCT02253654, source copy `cardio:ctgov-nct02253654-2017-05-19`, retrieved 2026-10-26)
- Countries: United States; Puerto Rico (ClinicalTrials.gov record NCT02253654, source copy `cardio:ctgov-nct02253654-2017-05-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02253654-2017-05-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
- Condition: Renal Insufficiency, Chronic
- Condition: Anemia
- Condition: Renal Dialysis
- Condition: Erythrocyte Transfusion
- Intervention (Drug): Epoetin alfa
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: bd952552491c12660edf9955477dcbb063aa251c07ecac694f8c511194f81467
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
